What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

R. Danesi; Y. M.D. Lo; M. Oellerich; J. Beck; S. Galbiati; M. Del Re; E. Lianidou; M. Neumaier; R. H.N. van Schaik

doi:10.1016/j.cca.2021.05.033

What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

R. Danesi, Y. M.D. Lo, M. Oellerich, J. Beck, S. Galbiati, M. Del Re, E. Lianidou, M. Neumaier, R. H.N. van Schaik^*

^*Corresponding author for this work

Clinical Chemistry

Research output: Contribution to journal › Article › Academic › peer-review

27 Citations (Scopus)

Abstract

The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.

Original language	English
Pages (from-to)	168-171
Number of pages	4
Journal	Clinica Chimica Acta
Volume	520
DOIs	https://doi.org/10.1016/j.cca.2021.05.033
Publication status	Published - Sept 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors

Access to Document

10.1016/j.cca.2021.05.033

Cite this

Danesi, R., Lo, Y. M. D., Oellerich, M., Beck, J., Galbiati, S., Re, M. D., Lianidou, E., Neumaier, M., & van Schaik, R. H. N. (2021). What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. Clinica Chimica Acta, 520, 168-171. https://doi.org/10.1016/j.cca.2021.05.033

@article{929f83cc20c54442918b489b150809f0,

title = "What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA",

abstract = "The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.",

author = "R. Danesi and Lo, {Y. M.D.} and M. Oellerich and J. Beck and S. Galbiati and Re, {M. Del} and E. Lianidou and M. Neumaier and {van Schaik}, {R. H.N.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = sep,

doi = "10.1016/j.cca.2021.05.033",

language = "English",

volume = "520",

pages = "168--171",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

}

Danesi, R, Lo, YMD, Oellerich, M, Beck, J, Galbiati, S, Re, MD, Lianidou, E, Neumaier, M & van Schaik, RHN 2021, 'What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA', Clinica Chimica Acta, vol. 520, pp. 168-171. https://doi.org/10.1016/j.cca.2021.05.033

TY - JOUR

T1 - What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

AU - Danesi, R.

AU - Lo, Y. M.D.

AU - Oellerich, M.

AU - Beck, J.

AU - Galbiati, S.

AU - Re, M. Del

AU - Lianidou, E.

AU - Neumaier, M.

AU - van Schaik, R. H.N.

PY - 2021/9

Y1 - 2021/9

N2 - The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.

AB - The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.

UR - http://www.scopus.com/inward/record.url?scp=85107801437&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2021.05.033

DO - 10.1016/j.cca.2021.05.033

M3 - Article

C2 - 34081934

AN - SCOPUS:85107801437

SN - 0009-8981

VL - 520

SP - 168

EP - 171

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

ER -

What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this